

April 1, 2015



# Viveve Announces Distribution Partnership With Global DIA Solutions S.L. of Spain

## Viveve(R) Treatment Now Available in 3 Countries in Europe

SUNNYVALE, CA -- (Marketwired) -- 04/01/15 -- Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced a new distribution partnership with Global DIA Solutions S.L. ("GDS"), a distributor of medical devices based in Barcelona, Spain with offices in Madrid and Valencia. This partnership combines GDS's expertise in building new medical device markets throughout Spain with Viveve's innovative product for treating vaginal laxity. The Viveve® Treatment is now available throughout the United Kingdom, Ireland, and Spain.

"Launching the globally patented Viveve System, which provides a safe, painless treatment for vaginal laxity, in Spain represents a great milestone for Viveve. Vaginal laxity is a medical condition that we believe remains ineffectively addressed for millions of women worldwide. As evidenced by the Spanish enrollment in the VIVEVE I study, the first randomized controlled study for vaginal laxity, the interest in Spain for the Viveve Treatment is significant. Working with GDS to introduce the procedure into Spain will help to ensure that physicians receive the best possible training and support as they begin offering the treatment," said Patricia Scheller, the Chief Executive Officer of Viveve.

Global DIA Solutions offers innovative solutions to healthcare professionals and has a history of offering clinically proven, cutting-edge technologies. The experienced management team focuses on patient satisfaction and providing exemplary clinical support for its customers.

"Global DIA Solutions is proud to add the Viveve System to its portfolio. It aligns perfectly with our mission to provide pioneering technologies to our customers. Now women who have this very common and frustrating condition will have access to a clinically proven procedure that is aimed at reducing vaginal laxity and restoring sexual satisfaction," said Jorge Alorda Guibernau, Sole Administrator of Global DIA Solutions. "We are truly excited to be the exclusive Spanish distributor of the new Viveve System, offering this unique product to physicians and their female patients and contributing to the improvement of women's sexual health."

### **About Viveve**

Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve® System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with

only one treatment session. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at [www.viveve.com](http://www.viveve.com).

### ***Safe Harbor Statement***

All statements in this press release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at [www.sec.gov](http://www.sec.gov). Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

*Viveve is a registered trademark of Viveve, Inc.*

Contact:

Investor Relations

Amato and Partners, LLC

90 Park Avenue, 17th Floor

New York, NY 10016

212.430.0362

[info@amatoandpartners.com](mailto:info@amatoandpartners.com)

Source: Viveve Medical, Inc.